公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)! YZ剂描述: 产品名称:Entinostat (MS-275, SNDX-275) 产品别名:恩替诺特 英文别名:MS-275;SNDX-275 靶点:HDAC1 ,HDAC3 CAS:209783-80-2 纯度:>98% 外观:白色粉末 保存方法:store at -20℃ for one year(Powder); in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months. 描述: Entinostat (MS-275)强烈YZHDAC1和HDAC3,无细胞试验中IC50分别为0.51 μM和1.7 μM,YZ作用强于HDACs 4, 6, 8,和10。 溶解性:DMSO : 37.6 mg/mL (100 mM) 体外研究: MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. 体内研究:MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. 产品信息订购: 产品货号 | 产品名称 | 规格 | 价格 | 大包装及货期 | abs812019 | Entinostat (MS-275, SNDX-275) | 100mg | 1170 | 立即咨询 | 产品更多信息请进入爱必信网站咨询 |